Fluidigm Corporation (FLDM) : Zacks Investment Research ranks Fluidigm Corporation (FLDM) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 2, which indicates as a Buy.
Fluidigm Corporation (FLDM) : 4 Wall Street analysts covering Fluidigm Corporation (FLDM) believe that the average level the stock could reach for the short term is $11.63. The maximum price target given is $14 and the minimum target for short term is around $10, hence the standard deviation is calculated at $1.89.
Shares of Fluidigm Corporation appreciated by 4.95% during the last five trading days but lost 4.61% on a 4-week basis. Fluidigm Corporation is up 0.98% in the last 3-month period. Year-to-Date the stock performance stands at -13.78%. Fluidigm Corporation (NASDAQ:FLDM): On Tuesdays trading session , Opening price of the stock was $9.43 with an intraday high of $9.47. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $9.22. However, the stock managed to close at $9.32, a loss of 0.85% for the day. On the previous day, the stock had closed at $9.4. The total traded volume of the day was 170,682 shares.
Fluidigm Corporation creates, manufactures and market technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Companys core microfluidics and mass cytometry technologies. The Company also offers instruments and consumables to academic institutions, clinical laboratories, pharmaceutical, biotechnology and agricultural biotechnology (Ag-Bio) companies. The Company sells technologies and life-science tools, including analytical and preparatory systems for genomic and proteomic analysis, and consumables, including Integrated Fluidic Circuits (IFCs), assays, and reagents. The Companys products include C1 Single-Cell Auto Prep System; Access Array System; Biomark HD System; EP1 System; CyTOF 2 System; IFCs include C1 IFCs; Access Array IFC; Dynamic Array IFCs; Digital Array IFCs; Flex Six IFC; Access Array Target-Specific Primers, and Maxpar Reagents, among others.